Population pharmacokinetics of therapeutic monoclonal antibodies.
A growing number of population pharmacokinetic analyses of therapeutic monoclonal antibodies (mAbs) have been published in the scientific literature. The aims of this article are to summarize the findings from these studies and to relate the findings to the general pharmacokinetic and structural characteristics of therapeutic mAbs. A two-compartment model was used in the majority of the population analyses to describe the disposition of the mAb. Population estimates of the volumes of distribution in the central (V(1)) and peripheral (V(2)) compartments were typically small, with median (range) values of 3.1 (2.4-5.5) L and 2.8 (1.3-6.8) L, respectively. The estimated between-subject variability in the V(1) was usually moderate, with a median (range) coefficient of variation (CV) of 26% (12-84%). Between-subject variability in other distribution-related parameters such as the V(2) and intercompartmental clearance were often not estimated. Although the pharmacokinetic models used most frequently in the population analyses were models with linear clearance, other models with nonlinear, or parallel linear and nonlinear clearance pathways were also applied, as many therapeutic mAbs are eliminated via saturable target-mediated mechanisms. Population estimates of the maximum elimination rate (V(max)) and the mAb concentration at which elimination was at half maximum for Michaelis-Menten-type elimination pathways varied considerably among the different therapeutic mAbs. However, estimates of the total clearance (CL) of mAbs with linear clearance characteristics and of the clearance of mAbs via the linear clearance pathway (CL(L)) with parallel linear and nonlinear clearance were quite similar for the different mAbs and typically ranged from 0.2 to 0.5 L/day, which is relatively close to the estimated clearance of endogenous IgG of 0.21 L/day. The between-subject variability in the V(max), CL and CL(L) was moderate to high, with estimated CVs ranging from 15% to 65%. Measures of body size were the covariates most commonly identified as influencing the pharmacokinetics of therapeutic mAbs. In summary, many features of the population pharmacokinetics of currently used therapeutic mAbs are similar, despite differences in their pharmacological targets and studied patient populations.
Dirks
Nathanael L
NL
Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA.
Meibohm
Bernd
B
D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D013329:Structure-Activity Relationship
D000911:Antibodies, Monoclonal
J Pharmacokinet Biopharm. 1999 Aug;27(4):397-420
10826130
J Pharmacokinet Pharmacodyn. 2007 Oct;34(5):687-709
17636457
Trends Immunol. 2006 Jul;27(7):343-8
16731041
J Pharmacokinet Pharmacodyn. 2008 Oct;35(5):573-91
19005743
Br J Clin Pharmacol. 2007 May;63(5):548-61
17096680
Physiol Rev. 2003 Jul;83(3):871-932
12843411
J Pharmacokinet Biopharm. 1994 Jun;22(3):229-51
7884651
Clin Pharmacol Ther. 2001 Apr;69(4):201-9
11309548
J Clin Pharmacol. 2007 Sep;47(9):1104-18
17766698
J Pharmacol Exp Ther. 2008 Aug;326(2):555-62
18460643
Clin Pharmacol Ther. 2001 Jun;69(6):387-99
11406736
Invest New Drugs. 2004 Jan;22(1):39-52
14707493
AAPS J. 2005 Oct 05;7(2):E475-87
16353925
Cancer Chemother Pharmacol. 2005 Oct;56(4):361-9
15868146
J Immunol. 2004 Feb 15;172(4):2021-9
14764666
J Clin Rheumatol. 2007 Dec;13(6):355-8
18176149
Clin Immunol. 2007 Feb;122(2):146-55
17046328
J Clin Oncol. 2003 Nov 1;21(21):3940-7
12975461
Nat Rev Immunol. 2007 Sep;7(9):715-25
17703228
J Clin Oncol. 2004 Jan 1;22(1):175-84
14701780
J Clin Invest. 1970 Apr;49(4):673-80
5443170
Antimicrob Agents Chemother. 1999 May;43(5):1183-8
10223933
J Clin Pharmacol. 2008 Mar;48(3):267-78
18218786
Drug Discov Today. 2006 Jan;11(1-2):81-8
16478695
J Clin Pharmacol. 2009 Feb;49(2):162-75
19179295
J Clin Pharmacol. 2009 Oct;49(10):1142-56
19723673
Biologics. 2008 Dec;2(4):645-53
19707445
Immunol Today. 1997 Dec;18(12):592-8
9425738
Endocrinology. 2001 Dec;142(12):5050-5
11713196
Curr Pharm Biotechnol. 2008 Dec;9(6):423-30
19075682
Blood. 2002 Feb 1;99(3):754-8
11806974
J Clin Pharmacol. 2007 May;47(5):553-65
17379759
J Clin Oncol. 2008 Apr 10;26(11):1789-96
18347005
Int Immunol. 2003 Feb;15(2):187-95
12578848
Br J Clin Pharmacol. 2007 Sep;64(3):278-91
17506867
J Clin Pharmacol. 2005 Jul;45(7):792-801
15951469
J Clin Pharmacol. 2009 Sep;49(9):1012-24
19620385
Am J Physiol Renal Physiol. 2002 Feb;282(2):F358-65
11788451
Immunol Res. 1997 Feb;16(1):29-57
9048207
J Cell Sci. 2000 Apr;113 ( Pt 7):1277-85
10704378
J Pharm Sci. 2002 Jan;91(1):18-31
11782894
Clin Cancer Res. 2004 Nov 15;10(22):7555-65
15569986
Br J Clin Pharmacol. 2004 Oct;58(4):378-89
15373930
Br J Clin Pharmacol. 2001 Feb;51(2):177-80
11259992
J Biol Chem. 2002 Aug 2;277(31):28038-50
12023961
Clin Pharmacokinet. 2007;46(5):417-32
17465640
J Pharmacokinet Biopharm. 1999 Apr;27(2):213-30
10567956
Pharm Res. 2005 Jul;22(7):1088-100
16028009
Eur J Clin Pharmacol. 2009 Dec;65(12):1211-28
19756557
J Clin Invest. 1999 Oct;104(7):903-11
10510331
Clin Pharmacol Ther. 1998 Jul;64(1):66-72
9695721
Annu Rev Pharmacol Toxicol. 1992;32:185-209
1605567
AAPS J. 2005 Oct 05;7(2):E363-73
16353916
Ann Pharmacother. 2004 Oct;38(10):1702-6
15328391
Pharm Res. 1990 Feb;7(2):167-9
2137911
Clin Pharmacol Ther. 1994 Sep;56(3):248-52
7924119
Ther Drug Monit. 2008 Aug;30(4):523-9
18641542
J Cell Sci. 1999 Jul;112 ( Pt 14):2291-9
10381385
Br J Cancer. 2008 Mar 11;98(5):900-6
18319714
J Clin Pharmacol. 2007 Feb;47(2):227-37
17244774
Int Immunol. 2001 Dec;13(12):1551-9
11717196
Aliment Pharmacol Ther. 2004 Mar 1;19(5):511-9
14987319
J Pharm Sci. 2004 Sep;93(9):2184-204
15295780
Pharm Res. 2006 Jun;23(6):1275-84
16715358
J Pharmacol Exp Ther. 2005 Apr;313(1):345-51
15579493
Lancet. 1966 Nov 19;2(7473):1087-93
4162525
Biochem Pharmacol. 2006 Jun 28;72(1):1-10
16469301
Pediatr Transplant. 2008 Jun;12(4):447-55
18466432
Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):803-12
19505189
Eur J Pharm Biopharm. 2007 Nov;67(3):759-65
17499981
J Clin Oncol. 2000 Feb;18(4):904-14
10673534
Cancer Chemother Pharmacol. 2008 Oct;62(5):779-86
18205003
Clin Pharmacol Ther. 1999 Sep;66(3):246-57
10511060
Clin Pharmacokinet. 2005;44(4):331-47
15828849
J Clin Pharmacol. 2008 Jun;48(6):681-95
18401017
Biologics. 2008 Jun;2(2):223-8
19707356
Clin Dev Immunol. 2004 Sep-Dec;11(3-4):205-13
15559365
Anticancer Drugs. 2007 Jan;18(1):7-15
17159497
J Clin Pharmacol. 2007 Mar;47(3):383-96
17322150
Prog Allergy. 1969;13:1-110
4186070
AAPS J. 2010 Mar;12(1):33-43
19924542
Hum Immunol. 2001 Feb;62(2):93-105
11182218
Curr Med Chem. 2007;14(18):1978-87
17691940
Clin Pharmacol Ther. 2008 Nov;84(5):548-58
18784655
J Clin Pharmacol. 2005 Apr;45(4):468-76
15778428
Br J Cancer. 1999 Dec;81(8):1419-25
10604742
J Pharm Sci. 2004 Nov;93(11):2645-68
15389672
Clin Cancer Res. 2006 Nov 1;12(21):6517-22
17065274